Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abaxis, Inc. stock logo
ABAX
Abaxis
$83.00
$0.00
$43.66
$83.98
N/AN/A167,754 shsN/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$131.66
+1.8%
$131.40
$110.33
$141.23
$229.31B0.76.97 million shs6.78 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$103.15
-1.0%
$103.56
$77.29
$108.94
$152.87B0.666.96 million shs5.34 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$480.26
+0.7%
$508.75
$425.00
$616.00
$172.16B1.592.19 million shs1.44 million shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abaxis, Inc. stock logo
ABAX
Abaxis
0.00%0.00%0.00%0.00%0.00%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%-2.04%+9.03%-2.32%+19.81%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.00%-0.07%-1.41%-2.69%+34.98%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.00%+2.17%-6.96%-14.79%+1.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abaxis, Inc. stock logo
ABAX
Abaxis
N/AN/AN/AN/AN/AN/AN/AN/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9113 of 5 stars
2.54.04.24.53.02.52.5
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.7352 of 5 stars
3.55.00.04.23.02.51.3
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.7019 of 5 stars
3.33.00.04.04.12.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abaxis, Inc. stock logo
ABAX
Abaxis
0.00
N/AN/AN/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.91
Moderate Buy$144.479.73% Upside
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.04
Buy$117.5013.91% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.63
Moderate Buy$595.9524.09% Upside

Current Analyst Ratings Breakdown

Latest ABAX, ABT, ISRG, and BSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$121.00 ➝ $124.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $135.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$110.00 ➝ $118.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$118.00 ➝ $124.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00 ➝ $125.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$125.00 ➝ $133.00
7/24/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$117.00 ➝ $123.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$547.00 ➝ $585.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$575.00 ➝ $595.00
7/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$590.00 ➝ $600.00
(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abaxis, Inc. stock logo
ABAX
Abaxis
N/AN/AN/AN/AN/AN/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$43.11B5.32$6.58 per share20.01$29.20 per share4.51
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$16.75B9.13$3.65 per share28.26$15.29 per share6.75
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$9.15B18.83$7.99 per share60.12$50.08 per share9.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abaxis, Inc. stock logo
ABAX
Abaxis
N/A$1.9642.35N/AN/AN/AN/AN/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.9816.5022.982.5032.43%18.32%10.71%10/15/2025 (Estimated)
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.6861.4031.932.4813.55%19.21%10.62%10/22/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$7.1766.9862.945.0328.51%14.56%12.93%10/16/2025 (Estimated)

Latest ABAX, ABT, ISRG, and BSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.72$0.75+$0.03$0.53$4.89 billion$5.06 billion
7/22/2025Q2 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.93$2.19+$0.26$1.81$2.35 billion$2.44 billion
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abaxis, Inc. stock logo
ABAX
Abaxis
$0.720.87%N/A36.73%N/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.79%N/A29.57%54 Years
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A

Latest ABAX, ABT, ISRG, and BSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abaxis, Inc. stock logo
ABAX
Abaxis
N/AN/AN/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.25
1.82
1.30
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.49
1.37
0.82
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
5.17
4.18

Institutional Ownership

CompanyInstitutional Ownership
Abaxis, Inc. stock logo
ABAX
Abaxis
90.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%

Insider Ownership

CompanyInsider Ownership
Abaxis, Inc. stock logo
ABAX
Abaxis
4.30%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abaxis, Inc. stock logo
ABAX
Abaxis
N/AN/AN/AOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
15,638358.48 million355.97 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abaxis stock logo

Abaxis NASDAQ:ABAX

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$131.66 +2.38 (+1.84%)
Closing price 08/15/2025 03:58 PM Eastern
Extended Trading
$131.61 -0.05 (-0.04%)
As of 08/15/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$103.15 -1.00 (-0.96%)
Closing price 08/15/2025 03:59 PM Eastern
Extended Trading
$103.37 +0.22 (+0.21%)
As of 08/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$480.26 +3.18 (+0.67%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$479.80 -0.46 (-0.10%)
As of 08/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.